Abstract:The myeloid-derived suppressor cell (MDSC)-mediated immunosuppressive tumor microenvironment (TME), where tumor hypoxia counts for much, has greatly compromised the outcome of cancer immunotherapy. Here, we demonstrated a strategy for selectively clearing intratumoral MDSCs. Specifically, 2-[2-[2-chloro-3-[(1,3-dihydro-3,3-dimethyl-1-propyl-2H-indol-2-ylidene)ethylidene]-1-cyclohexen-1-yl]ethenyl]-3,3-dimethyl-1-propylindolium iodide (IR-780) and metformin (Met) were coloaded into mesoporous silica nanoparticles (MSNs) with CeO2 as the gatekeepers. Controlled release of cargos was achieved upon etching CeO2 with endogenous H2O2. Apart from the drug release, oxygen (O2) was also generated in this process. Importantly, the engagement of Met significantly inhibited mitochondrial respiration, thus working like an O2 economizer. Consequently, the populations and functions of tumor-infiltrated MDSCs were both dramatically reduced through selective alleviation of hypoxia at tumor sites, thus contributing to boosted immune responses. Additionally, the accumulated O2 enhanced IR780-mediated photodynamic therapy, which synergistically strengthened the antitumor efficacy of the platform. To the best of our knowledge, this is the first time to employ an O2-generated and -economized nanoplatform for selectively anergizing MDSC-mediated immunosuppression. We expect that this strategy will shed new light on the clinical cancer immunotherapy treatment.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c18180?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c18180</a>.In vitro release profile of IR780 and Met from CeO2@/Met nanoparticles in plasma. Degradation of H2O2 by CeO2 NPs and the release of O2. Positive area of Ki-67 in tumor tissues after indicated treatments. Positive area of TUNEL in tumor tissues after indicated treatments. Survival curves of B16F10 tumor-bearing mice that received indicated treatments as displayed. Plasma concentration–time curves of CeO2@/Met in mice after intravenous injection. In vivo tissue distribution in B16F10 tumor-bearing mice intravenously injected with indicated treatments at different time points. Quantification of the metastatic nodules on the lung surface of mice under different treatments. Q-PCR analyzed the mRNA level of HIF-α in tumor tissues from B16F10 tumor-bearing mice subjected to indicated treatments. Relative intensity of HIF-1α protein expression by western blotting. Standardized uptake values (SUVs) in solid tumor regions obtained from in vivo PET images taken at 1 h after the injection of 18F-MISO. Relative quantification of MDSCs (CD11b+Gr-1+) in tumor tissues following different treatments. Relative quantification of CTLs (CD3+CD8+) in tumor tissues following different treatments. ELISA assay for IL-10 and TGF-β. Relative intensity of PD-L1 protein expression by western blotting. Histology of the mouse organs collected 21 days after the intravenous injection of CeO2@/Met (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c18180/suppl_file/am0c18180_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

ROS Scavenging Nanozyme Modulates Immunosuppression for Sensitized Cancer Immunotherapy

ROS Scavenging Nanozyme Modulates Immunosuppression for Sensitized Cancer Immunotherapy (Adv. Healthcare Mater. 21/2023)

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

Circumventing Myeloid-Derived Suppressor Cell-Mediated Immunosuppression Using an Oxygen-Generated and -Economized Nanoplatform

Augmenting Immunotherapy via Bioinspired MOF-Based ROS Homeostasis Disruptor with Nanozyme-Cascade Reaction

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Precise Regulation of Reactive Oxygen Species in Tumor Microenvironment for Alleviating Inhibitory Immunogenic Cell Death

Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy

Dual Oxygen-Supply Immunosuppression-Inhibiting Nanomedicine to Avoid the Intratumoral Recruitment of Myeloid-Derived Suppressor Cells

Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway

Bypassing the Immunosuppression of Myeloid‐Derived Suppressor Cells by Reversing Tumor Hypoxia Using a Platelet‐Inspired Platform

Reactive oxygen species-powered cancer immunotherapy: Current status and challenges

Zinc-Based ROS Amplifiers Trigger Cancer Chemodynamic/Ion Interference Therapy Through Self-Cascade Catalysis

A cascade nanoreactor for enhancing sonodynamic therapy on colorectal cancer via synergistic ROS augment and autophagy blockage

Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity

Reversing the immunosuppressive microenvironment with reduced redox level by microwave-chemo-immunostimulant Ce–Mn MOF for improved immunotherapy

Reactive Oxygen Species in Anticancer Immunity: A Double-Edged Sword

Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy

Multifaceted Elevation of ROS Generation for Effective Cancer Suppression

Multi‐Enzyme Nanoparticles as Efficient Pyroptosis and Immunogenic Cell Death Inducers for Cancer Immunotherapy

A Salicylic Acid-Based Hypoxia-Response Chemodynamic Nanomedicine Via Modulation of Immunosuppression Tumor Microenvironment for Enhanced Antitumor Immunotherapy